Abiomed, a developer of heart support technologies, has reported an upward trend in the third quarter of 2012, compared with the third quarter of 2011, bolstered by strong sales of Impella.
The Danvers, Mass.-based company has reported third quarter fiscal 2012 revenue of $32.2 million, up 18 percent compared with revenue of $27.2 million in the same period of fiscal 2011.
The GAAP net income was reported to be $2.9 million in the third quarter of 2012, compared with a GAAP net loss of $0.8 million. The fiscal third quarter worldwide Impella revenue totaled $27.7 million, up 31 percent, compared with revenue of $21.2 million during the same period of the prior year.
Also, Abiomed said that the U.S. Impella revenue of $25.5 million was up 30 percent from the prior year. The company said that an additional 37 U.S. hospitals purchased Impella 2.5 during the quarter. There are now 605 Impella U.S. customer sites.
The company said its total U.S. revenue of $29.6 million was up 17 percent from $25.3 million in the prior year's third quarter. Revenue from outside the U.S. totaled $2.6 million, up 37 percent from $1.9 million in the prior year's third quarter.
Based on their results, Abiomed updated its full fiscal year 2012 revenue to be in the range of $122 million to $125 million compared with previous guidance of $120 million to $125 million.